Leukemia stem cell-based method aids relapse prediction in acute myeloid leukemia
An assay that uses leukemia stem cells (LSCs) to assess measurable residual disease (MRD) outperforms traditional methods in patients with acute myeloid leukemia (AML), according to a study published online Aug. 23 in Bone Marrow Transplantation.